National Agency of Drug and Food Control of Indonesia

Global Recombinant Vaccines Market to Surpass US$ 1,809.7 Million by 2030 - Coherent Market Insights

Retrieved on: 
Wednesday, June 22, 2022

SEATTLE, June 22, 2022 /PRNewswire/ --According to Coherent Market Insights, the global recombinant vaccines market is estimated to be valued at US$ 1,116.1 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, June 22, 2022 /PRNewswire/ --According to Coherent Market Insights, the global recombinant vaccines market is estimated to be valued at US$ 1,116.1 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Recombinant Vaccines Market:
    Major players operating in market are focusing on adopting strategies such as product approvals, which is expected to drive market growth over the forecast period.
  • Global recombinant vaccines market is expected to exhibit a CAGR of 6.2% during the forecast period due to increasing prevalence of various infections such as hepatitis B.
  • Among product types, the subunit recombinant vaccines segment is expected to dominate segment growth over the forecast period, owing to increased patent applications and allowance to key players for subunit recombinant vaccines.

GPDRR: Indonesia offers sustainable resilience to tackle disaster risk

Retrieved on: 
Thursday, May 26, 2022

JAKARTA, Indonesia, May 26, 2022 /PRNewswire/ -- At the 2022 Global Platform for Disaster Risk Reduction (GPDRR) event, theGovernment of Indonesia offered the world the concept of sustainable resilienceas a solution to address the challenges of systemic disaster risk.

Key Points: 
  • JAKARTA, Indonesia, May 26, 2022 /PRNewswire/ -- At the 2022 Global Platform for Disaster Risk Reduction (GPDRR) event, theGovernment of Indonesia offered the world the concept of sustainable resilienceas a solution to address the challenges of systemic disaster risk.
  • The sustainable resilience concept is considered to be a solution to tackle allforms of disasters, including facing a pandemic and concurrently supporting theimplementation of the Sustainable Development Goals (SDGs), Jokowi remarked.
  • She also affirmed that Indonesia is a critical partner that has taught theworld a lot about disaster risk reduction.
  • Meanwhile, the United Nations Office for Disaster Risk Reduction (UNDRR)Director Ricardo Mena lauded Indonesia as a country that is leading in theglobal efforts for disaster risk reduction.

CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia

Retrieved on: 
Tuesday, March 22, 2022

The MOH Malaysia recommends using Convidecia as a heterologous booster for individuals aged 18 and above who have been administered two doses of inactivated COVID-19 vaccine at least three months prior.

Key Points: 
  • The MOH Malaysia recommends using Convidecia as a heterologous booster for individuals aged 18 and above who have been administered two doses of inactivated COVID-19 vaccine at least three months prior.
  • The BPOM recommends that adults who have received inactivated COVID-19 vaccines opt for either Convidecia or an mRNA vaccine as a booster.
  • In addition to Malaysia and Indonesia, Convidecia has been approved for use as a heterologous booster in China and Argentina in national vaccination programs in February 2022 and November 2021, respectively.
  • Recent studies[1]showed that using Convidecia as a heterologous booster, either through intramuscular injection or inhalation, generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.

PathoQuest Receives GMP Certification for Its NGS-based Quality Control Testing Services of Biological Drugs

Retrieved on: 
Wednesday, November 24, 2021

PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.

Key Points: 
  • PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
  • View the full release here: https://www.businesswire.com/news/home/20211124005881/en/
    This GMP certification acknowledges PathoQuest's testing activities meet the established high-quality control standards required by the biopharmaceutical industry.
  • The GMP certification for our biosafety testing services completes our GLP certificate obtained in January 2020 and the Pharmaceutical Establishment status achieved in September 2020.
  • Gaining this GMP certification is a major milestone in the implementation of PathoQuests growth strategy and strengthens our leadership in the quality control testing of biologics, commented Jean-Francois Brepson, PathoQuests CEO.